Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Stage

Series B | Alive

Total Raised

$10.74M

Last Raised

$10M | 7 yrs ago

About MYR

MYR is a German biotechnology company developing Myrcludex B, a drug for the treatment of chronic hepatitis B and delta virus infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.

MYR Headquarter Location

Eiermarkt 3 c

Burgwedel, D-30938,

Germany

49 5139 894379

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MYR

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MYR is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

MYR Patents

MYR has filed 3 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Hepatology
  • Autoantibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/12/2018

2/23/2021

Transcription factors, Hepatology, Rare diseases, Autoimmune diseases, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/12/2018

00/00/0000

00/00/0000

Grant Date

2/23/2021

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Hepatology, Rare diseases, Autoimmune diseases, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.